Poxvirus vector-based HIV vaccines

Giuseppe Pantaleo, Mariano Esteban, Bertram Jacobs, Jim Tartaglia

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose of review: In this review, we will provide the scientific rationale for the use of poxvirus vectors in the field of HIV vaccines, the immunological profile of the vaccine-induced immune responses, an update on the current use of poxvirus vector-based vaccines in HIV vaccine clinical trials, and the development of new modified poxvirus vectors with improved immunological profile. Recent Findings: An Ad5-HIV vaccine was tested in a phase IIb clinical trial (known as the Step trial). Vaccinations in the Step trial were discontinued because the vaccine did not show any effect on acquisition of infection and on viral load. After the disappointing failure of the Step trial, the field of HIV vaccine has regained enthusiasm and vigour due to the promising protective effect observed in the phase III efficacy trial (known as RV-144) performed in Thailand which has tested a poxvirus-gp120 combination. Summary: The RV-144 phase III has provided for the first time evidence that an HIV vaccine can prevent HIV infection. The results from the RV-144 trial are providing the scientific rationale for the future development of the HIV vaccine field and for designing future efficacy trials.

Original languageEnglish (US)
Pages (from-to)391-396
Number of pages6
JournalCurrent Opinion in HIV and AIDS
Volume5
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Poxviridae
AIDS Vaccines
Vaccines
Clinical Trials
Thailand
Viral Load
HIV Infections
Vaccination
Infection
erdosteine

Keywords

  • HIV
  • poxvirus vectors
  • vaccines

ASJC Scopus subject areas

  • Hematology
  • Oncology(nursing)
  • Immunology
  • Infectious Diseases
  • Virology
  • Oncology

Cite this

Poxvirus vector-based HIV vaccines. / Pantaleo, Giuseppe; Esteban, Mariano; Jacobs, Bertram; Tartaglia, Jim.

In: Current Opinion in HIV and AIDS, Vol. 5, No. 5, 09.2010, p. 391-396.

Research output: Contribution to journalArticle

Pantaleo, Giuseppe ; Esteban, Mariano ; Jacobs, Bertram ; Tartaglia, Jim. / Poxvirus vector-based HIV vaccines. In: Current Opinion in HIV and AIDS. 2010 ; Vol. 5, No. 5. pp. 391-396.
@article{648fc76678eb4bc4a6e0661ed7e4635d,
title = "Poxvirus vector-based HIV vaccines",
abstract = "Purpose of review: In this review, we will provide the scientific rationale for the use of poxvirus vectors in the field of HIV vaccines, the immunological profile of the vaccine-induced immune responses, an update on the current use of poxvirus vector-based vaccines in HIV vaccine clinical trials, and the development of new modified poxvirus vectors with improved immunological profile. Recent Findings: An Ad5-HIV vaccine was tested in a phase IIb clinical trial (known as the Step trial). Vaccinations in the Step trial were discontinued because the vaccine did not show any effect on acquisition of infection and on viral load. After the disappointing failure of the Step trial, the field of HIV vaccine has regained enthusiasm and vigour due to the promising protective effect observed in the phase III efficacy trial (known as RV-144) performed in Thailand which has tested a poxvirus-gp120 combination. Summary: The RV-144 phase III has provided for the first time evidence that an HIV vaccine can prevent HIV infection. The results from the RV-144 trial are providing the scientific rationale for the future development of the HIV vaccine field and for designing future efficacy trials.",
keywords = "HIV, poxvirus vectors, vaccines",
author = "Giuseppe Pantaleo and Mariano Esteban and Bertram Jacobs and Jim Tartaglia",
year = "2010",
month = "9",
doi = "10.1097/COH.0b013e32833d1e87",
language = "English (US)",
volume = "5",
pages = "391--396",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Poxvirus vector-based HIV vaccines

AU - Pantaleo, Giuseppe

AU - Esteban, Mariano

AU - Jacobs, Bertram

AU - Tartaglia, Jim

PY - 2010/9

Y1 - 2010/9

N2 - Purpose of review: In this review, we will provide the scientific rationale for the use of poxvirus vectors in the field of HIV vaccines, the immunological profile of the vaccine-induced immune responses, an update on the current use of poxvirus vector-based vaccines in HIV vaccine clinical trials, and the development of new modified poxvirus vectors with improved immunological profile. Recent Findings: An Ad5-HIV vaccine was tested in a phase IIb clinical trial (known as the Step trial). Vaccinations in the Step trial were discontinued because the vaccine did not show any effect on acquisition of infection and on viral load. After the disappointing failure of the Step trial, the field of HIV vaccine has regained enthusiasm and vigour due to the promising protective effect observed in the phase III efficacy trial (known as RV-144) performed in Thailand which has tested a poxvirus-gp120 combination. Summary: The RV-144 phase III has provided for the first time evidence that an HIV vaccine can prevent HIV infection. The results from the RV-144 trial are providing the scientific rationale for the future development of the HIV vaccine field and for designing future efficacy trials.

AB - Purpose of review: In this review, we will provide the scientific rationale for the use of poxvirus vectors in the field of HIV vaccines, the immunological profile of the vaccine-induced immune responses, an update on the current use of poxvirus vector-based vaccines in HIV vaccine clinical trials, and the development of new modified poxvirus vectors with improved immunological profile. Recent Findings: An Ad5-HIV vaccine was tested in a phase IIb clinical trial (known as the Step trial). Vaccinations in the Step trial were discontinued because the vaccine did not show any effect on acquisition of infection and on viral load. After the disappointing failure of the Step trial, the field of HIV vaccine has regained enthusiasm and vigour due to the promising protective effect observed in the phase III efficacy trial (known as RV-144) performed in Thailand which has tested a poxvirus-gp120 combination. Summary: The RV-144 phase III has provided for the first time evidence that an HIV vaccine can prevent HIV infection. The results from the RV-144 trial are providing the scientific rationale for the future development of the HIV vaccine field and for designing future efficacy trials.

KW - HIV

KW - poxvirus vectors

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=77955518218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955518218&partnerID=8YFLogxK

U2 - 10.1097/COH.0b013e32833d1e87

DO - 10.1097/COH.0b013e32833d1e87

M3 - Article

VL - 5

SP - 391

EP - 396

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 5

ER -